InvestorsHub Logo
Followers 167
Posts 35834
Boards Moderated 3
Alias Born 10/20/2019

Re: None

Wednesday, 01/25/2023 8:46:17 AM

Wednesday, January 25, 2023 8:46:17 AM

Post# of 2791
Excellent News today from $NBIO...

The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News